VTYX Q2 2025 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$29M

Net Income

-$27M

EPS (Diluted)

$-0.38

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$230M

Total Liabilities

$21M

Stockholders' Equity

$209M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$316,000	+100.0%
Operating Income	-$29M	-$36M	+17.9%
Net Income	-$27M	-$32M	+15.5%